Results 101 to 110 of about 7,229 (203)

Increasing CD4/CD8 ratio confirmed after two years of long-acting cabotegravir and rilpivirine in the SCohoLART study

Frontiers in Virology
BackgroundLong-acting (LA) cabotegravir plus rilpivirine (CAB/RPV) is an established maintenance option for virologically suppressed people with HIV (PWH), but long-term real-world data on immune balance and cardio-metabolic and renal markers remain ...
Gabriele Loi, Nicolò Capra, Riccardo Lolatto, Marcella Negri, Gaia Catalano, Flavia Passini, Nicolò Moschetta, Claudia Benelli, Silvia Nozza, Silvia Nozza, Antonella Castagna, Antonella Castagna, Camilla Muccini   +12 more
doaj   +1 more source

Implementation of long‐acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations

Journal of the International AIDS Society
Introduction Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long‐acting (LA) regimen recommended for maintaining HIV‐1 virological suppression.
Cassidy A. Gutner, Laurent Hocqueloux, Celia Jonsson‐Oldenbüttel, Linos Vandekerckhove, Berend J. vanWelzen, Laurence Slama, María Crusells‐Canales, Julián Olalla Sierra, Rebecca DeMoor, Jenny Scherzer, Mounir Ait‐Khaled, Gilda Bontempo, Martin Gill, Natasha Patel, Ronald D'Amico, Kai Hove, Bryan Baugh, Nicola Barnes, Monica Hadi, Emma L. Low, Savita Bakhshi Anand, Alison Hamilton, Harmony P. Garges, Maggie Czarnogorski   +23 more
doaj   +1 more source

Modelling the tail-phase pharmacokinetics of long-acting cabotegravir and rilpivirine from early pregnancy to postpartum at steady state. [PDF]

J Pharmacokinet Pharmacodyn
Atoyebi S, Waitt C, Olagunju A.
europepmc   +2 more sources

Susceptibility pattern of etravirine and rilpivirine in patients who failed nevirapine and efavirenz-based regimens.

, 2016
Susceptibility pattern of etravirine and rilpivirine in patients who failed nevirapine and efavirenz-based regimens.
Anchalee Avihingsanon (340691), Kiat Ruxrungtham (247724), Opass Putcharoen (2633791), Suwanna Mekprasan (2633794), Phairote Teeranaipong (2633797), Pirapon June Ohata (2633788), Sunee Sirivichayakul (7870)   +6 more
core   +1 more source

Successful initiation of fully parenteral antiretroviral therapy in a treatment-naïve person with HIV-1 infection and intestinal failure

HIV Research & Clinical Practice
Introduction In patients with severe surgical and gastrointestinal complications, standard oral combination antiretroviral therapy (ARV) may be temporarily impossible.
Krystof Sram, Hanus Rozsypal, Stanislav Sevela, Jakub Lhotan, David Jilich   +4 more
doaj   +1 more source

Process Development of a Novel Route to Rilpivirine Hydrochloride

An efficient synthetic route to access rilpivirine hydrochloride was designed and demonstrated on a multikilogram scale. The synthetic route uses two subsequent aromatic nucleophilic substitutions, conducted under carefully optimized conditions to access
Vincent Revil-Baudard (17934911), Solenne Kowalkowski (17934908), Laurent Petit (70825), Baptiste Fours (4920061), Kenny Delacroix (11884986), Marc Perez (1392346)   +5 more
core   +1 more source

Assessment of Failures of Long-acting Cabotegravir and Rilpivirine in a Real-world Treatment Setting

Fifty-eight people with HIV switched to long-acting cabotegravir and rilpivirine in a real-world clinic setting had higher discontinuation rates because of virologic failure, side effects, or nonadherence compared to clinical trials.
Payne, Shannon, Brar, Indira, Yared, Nicholas, Gudipati, Smitha   +3 more
core   +1 more source

Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial. [PDF]

Lancet Reg Health Southeast Asia
Kajeekul R, Ruenroengbun N, Wiwatrojanagul S, Kirdtongkum K, Chantaranothai W, Bin Khalid KE, Sirijatuphat R, Ngamprasertchai T.   +7 more
europepmc   +1 more source

Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study

Background. The life expectancy of people with human immunodeficiency virus (PWH) has significantly increased, thanks to combined antiretrovirals with improved potency and tolerability.
Marzolini, C., Marzolini, C, Bettonte, S., Battegay, M., Berton, M, Bettonte, S, Stader, F., Battegay, M, Stader, F, Berton, M.   +9 more
core   +1 more source

Sustained Virologic Suppression After Discontinuation of Long-acting Cabotegravir/Rilpivirine: A Two-case Series Highlighting Unexpected Heterogeneity in Pharmacokinetics and Viral Control. [PDF]

Open Forum Infect Dis
Marinosci A, Yerly S, Marzolini C, Calmy A.   +3 more
europepmc   +1 more source